Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gilead Sciences : to Donate 103,000 Vials of Veklury to Indonesia, Armenia

10/19/2021 | 09:52am EST


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
12/06Goldman Sachs Starts Gilead Sciences at Neutral With $80 Price Target
MT
12/04Gilead recalls vials of COVID-19 drug remdesivir due to glass contamination
AQ
12/03Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
AQ
12/02DOJ, SEC Charge Former Immunomedics Finance Chief With Insider Trading
DJ
12/02What COVID-19 vaccine and drug makers have to say about Omicron
RE
12/01GILEAD SCIENCES : Statement on Veklury« (Remdesivir) and the SARS-CoV-2 Omicron Variant
PU
11/30NRX Pharmaceuticals Shares Slide 16% After Soaring on COVID-19 Drug, Vaccine Updates
MT
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Regeneron's COVID-19 antibody drug may be less effective against Omicron
RE
11/30Gilead's Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Hi..
AQ
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Financials (USD)
Sales 2021 26 507 M - -
Net income 2021 7 187 M - -
Net Debt 2021 22 419 M - -
P/E ratio 2021 12,1x
Yield 2021 4,06%
Capitalization 87 368 M 87 368 M -
EV / Sales 2021 4,14x
EV / Sales 2022 4,31x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Last Close Price 69,65 $
Average target price 76,14 $
Spread / Average Target 9,31%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.19.55%87 180
BIONTECH SE310.30%67 585
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137
BEIGENE, LTD.21.58%30 750